Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crunch Time For 18 Products Seeking EU Approval, "No" Stays In Place for Radius

Executive Summary

Two drugs filed via the rarely-used used EU pediatric-use marketing authorization pathway are among 18 products up for an opinion from the European Medicines Agency this week on whether they should be approved. Also, Radius Health has already said its appeal has failed. What news will there be on Portola's appeal?

You may also be interested in...



OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No

The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.

OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No

The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.

Radius Braced For Second CHMP No For Abaloparatide

Another expected knockback by the European Medicines Agency's scientific committee is expected for Radius' lead product after the company revealed a negative trend vote for the osteoporosis therapy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel